Oragenics, Intrexon in deal to develop genetically modified probiotics

|About: Oragenics, Inc. (OGEN)|By:, SA News Editor

Oragenics (OGEN +3.7%) and Intrexon (XON +0.5%) establish an Exclusive Channel Collaboration for the development and commercialization of "genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus."

The companies intends to initially focus on a treatment for oral lesions associated with Behcet's. (PR)

Previous: XON, OGEN announce results from lantibiotics testing